SMAD4 Underexpression

CI-VAR-00004402Explore in graph →CIViC 282

Curated evidence

Evidence by cancer (5 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–5 of 5 evidence items across 4 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Head and Neck Squamous Cell Carcinoma1
SMAD4 Underexpression	Cetuximab	Predictive	D	Supports Resistance	3	accepted	EID720 In this study, SMAD4 underexpression was associated with an epithelial-to-mesenchymal transition and resistance to EGFR-directed treatment with Cetuximab. PMID 26046389 · Cheng et al., 2015 · Open in CIViC	civic
Lung Non-Small Cell Carcinoma1
SMAD4 Underexpression	Gemcitabine	Predictive	B	Supports Sensitivity Response	4	submitted	EID6437 Of the 28 individuals that received 30 treatments containing gemcitabine or etoposide, only 13 of them showed underexpression of SMAD4. Treatment with DNA topoisomerase inhibitors, especially gemcitab… (full text at CIViC) PMID 28577946 ·

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.

Malignant Pancreatic Neoplasm2
SMAD4 Underexpression	(prognostic)	Prognostic	B	Supports Better Outcome	4	submitted	EID6440 In patients with Pancreatic Cancer, about half of them show an under expression of SMAD4. There was no relationship between SMAD4 expression and OS, but PFS was much longer in patients with SMAD4 unde… (full text at CIViC) PMID 28534865 · Ormanns et al., 2017 · Open in CIViC	civic
SMAD4 Underexpression	(prognostic)	Prognostic	B	Supports Poor Outcome	4	submitted	EID6445 Using univariate analysis, the results showed that underexpression of SMAD4 had a strong relationship with poor OS in pancreatic cancer patients. More specifically, the underexpression of SMAD4 was re… (full text at CIViC) PMID 26947875 · Shugang et al., 2016 · Open in CIViC	civic

Malignant Prostate Neoplasm1
SMAD4 Underexpression	(prognostic)	Prognostic	B	Supports Poor Outcome	4	submitted	EID6462 The under expression of SMAD4 resulted in a higher Gleason score and a higher level of preoperative prostate specific antigen (PSA). It is considered for low levels of PSA to be normal. Patients with … (full text at CIViC) PMID 24272204 · Zhang et al., 2014 · Open in CIViC	civic